Knockdown of TRIM44 inhibits the progression of human epithelial ovarian cancer via the FOXM1-EZH2 signaling pathway

Fanling Meng, Jing Ding, Xihai Chen, Su-I Lin, Yuanlong Hu, Shuang Liu, Guangyue Shi, Yunlong He, Xin Ning, Jiaqi Zhu, Ruixue Zhao, Jing Ma, Sujing Ren, Rong Ma, Ning HuangResearch Square 2021 · DOI

Introduction

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, often diagnosed at advanced stages due to a lack of early symptoms. With a five-year survival rate of approximately 30%, there is an urgent need for novel biomarkers and therapeutic targets. The "tripartite motif-containing" (TRIM) family of proteins has recently gained attention for its role in cancer progression. This study focuses on TRIM44, investigating its biological function and clinical implications in EOC.

Methods

The research team employed a comprehensive experimental design:

  • Clinical Analysis: TRIM44 expression was compared between fresh EOC samples and normal ovarian tissues.
  • Gene Silencing: Lentivirus-mediated shRNA was used to knock down TRIM44 in SKOV3 and A2780 EOC cell lines.
  • Functional Assays: The impact of TRIM44 knockdown on cell proliferation, colony formation, migration, invasion, and apoptosis was evaluated using CCK-8 assays, Transwell filters, and flow cytometry.
  • In Vivo Studies: A nude mouse xenograft model was used to observe the effect of TRIM44 silencing on tumor growth over 23 days.
  • Mechanistic Investigation: Gene chip analysis and Ingenuity Pathway Analysis (IPA) were performed to identify the signaling pathways regulated by TRIM44.

Results

The study found that TRIM44 is significantly overexpressed in EOC tissues and cell lines.

Figure 1: Impact of TRIM44 knockdown on EOC cell proliferation, migration, and invasion.

Inhibition of Cancer Progression

Knocking down TRIM44 expression substantially suppressed the aggressive behavior of EOC cells. In vitro, cell proliferation was reduced by 54.14% in SKOV3 cells and 76.93% in A2780 cells by the fifth day. Migration and invasion were also significantly inhibited. These findings were mirrored in vivo, where TRIM44-silenced xenograft tumors showed significantly reduced growth compared to controls.

The FOXM1-EZH2 Signaling Pathway

Bioinformatics analysis revealed that TRIM44 regulates a vast network of 1,172 genes. The most critical discovery was the link between TRIM44 and the FOXM1-EZH2 signaling pathway. Silencing TRIM44 led to the downregulation of FOXM1 and EZH2, as well as their downstream targets CCNE2, CCND3, and BIRC5. This suggests that TRIM44 promotes EOC progression by activating this specific pathway, which in turn drives the cell cycle and inhibits apoptosis.

Conclusion

Collectively, these data suggest that TRIM44 acts as an oncogene in epithelial ovarian cancer. By regulating the FOXM1-EZH2 signaling axis, TRIM44 facilitates tumor growth and metastasis. These results provide novel insights into EOC tumorigenesis and highlight TRIM44 as a potential therapeutic target for treating ovarian carcinoma.

Summary updated

Abstract

<title>Abstract</title> <bold><italic>Background. </italic></bold>Tripartite motif‑containing protein 44 (TRIM44) was recently identified as a novel oncogene that is overexpressed in several types of human cancers. However, the biological functions of TRIM44 in epithelial ovarian cancer (EOC) remain unclear. Here, we aimed to investigate the role of TRIM44 in EOC and its clinical implications.<bold><italic>Methods. </italic></bold>The expression of TRIM44 in different ovarian cancer cell lines were detected by western blot. TRIM44 was knocked down by shRNA transfection. The in vitro proliferation, invasion, migration and apoptosis of ovarian cancer cells were detected by CCK8, colony formation assay, transwell filters, tube formation assay and flow cytometry analysis, respectively. The growth ability of xenograft tumors in vivo was examined by a nude mouse metastatic tumor model. Finally, we carried out gene chip analysis and IPA to analyze the potential gene network.<bold><italic>Results. </italic></bold><italic>H</italic>igh expression of TRIM44 was observed in EOC tissues and cell lines. Knockdown of TRIM44 expression substantially suppressed the proliferation, migration, invasion and colony-forming ability of EOC cells in vitro and attenuated tumor growth in vivo. Mechanistic studies showed that silencing TRIM44 dramatically down regulated the expression of FOXM1, EZH2, CCNE2, CCND3 and BIRC5 in EOC cells, at least in part through inactivation of the FOXM1-EZH2 signaling pathway.<bold><italic>Conclusion.</italic></bold> Collectively, these data suggest that TRIM44 downregulation inhibits the progression of EOC cells through the suppression of the FOXM1-EZH2 signaling pathway. These results provide novel insight into the role of TRIM44 in tumorigenesis and suggest it could be a potential therapeutic target of ovarian carcinoma.
BibTeX
@inproceedings{meng2021knockdown,
  author = {Fanling Meng and Jing Ding and Xihai Chen and Su-I Lin and Yuanlong Hu and Shuang Liu and Guangyue Shi and Yunlong He and Xin Ning and Jiaqi Zhu and Ruixue Zhao and Jing Ma and Sujing Ren and Rong Ma and Ning Huang},
  title = {{Knockdown of TRIM44 inhibits the progression of human epithelial ovarian cancer via the FOXM1-EZH2 signaling pathway}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-287714/v1},
}
Figure